Pantelitsa Protopapa, PhD

Pantelitsa Protopapa, PhD has extensive work experience in the field of oncology and cancer biology. Pantelitsa currently works as a Research Scientist at Adrestia Therapeutics since November 2022. Prior to that, from April 2022 to September 2022, they served as a Research Assistant at Barts Cancer Institute, Center for Haemato-Oncology. During this time, they also pursued their Doctor of Philosophy (PhD) in Oncology and Cancer Biology at Barts Cancer Institute, investigating the role of integrin αvβ8 in Pancreatic Adenocarcinoma (PDAC).

From September 2018 to March 2022, Pantelitsa worked at Queen Mary University of London, where they were involved in teaching and supervision activities. Pantelitsa also gained research experience at MiNA Therapeutics, working as a Research Scientist from November 2016 to June 2018.

Pantelitsa's journey in the field of research started with a summer placement at the University of Surrey's Cardiovascular Research laboratories in September 2014. Here, they gained exposure to various techniques such as Western blotting, tissue homogenization, and cell culture.

In 2013, Pantelitsa undertook a professional training year as a Pharmacovigilance Associate at PharSafer as part of their Sandwich degree. Pantelitsa'sresponsibilities included individual patient and clinical trial case review, data entry, literature reviewing for adverse drug reactions identification, and providing drug-inquiries related assistance to patients.

Pantelitsa's work experience began with a summer internship at The Cyprus Institute of Neurology & Genetics in June and July 2012.

Pantelitsa Protopapa, PhD, has a strong educational background in the field of oncology and cancer biology. Pantelitsa completed their Bachelor's Degree in Biomedical Sciences, General at the University of Surrey from 2011 to 2015. Following this, they pursued a Master's Degree in MRes Cancer Biology at Imperial College London, which they completed from 2015 to 2016. Pantelitsa went on to further advance their knowledge and expertise, obtaining a Doctor of Philosophy (PhD) from Queen Mary University of London, specializing in Oncology and Cancer Biology, a program they completed between 2018 and 2022. Additionally, they have also participated in the SysMIC - Quantitative skills for bioscience program at UCL in 2021 and 2022.